JP2016520050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520050A5 JP2016520050A5 JP2016512033A JP2016512033A JP2016520050A5 JP 2016520050 A5 JP2016520050 A5 JP 2016520050A5 JP 2016512033 A JP2016512033 A JP 2016512033A JP 2016512033 A JP2016512033 A JP 2016512033A JP 2016520050 A5 JP2016520050 A5 JP 2016520050A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- source
- nutritional composition
- acid
- egcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 30
- 235000016709 nutrition Nutrition 0.000 claims 16
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 11
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 11
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 11
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims 9
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims 2
- VEXDRERIMPLZLU-UHFFFAOYSA-N 3-hydroxy-2-methylbutanoic acid Chemical compound CC(O)C(C)C(O)=O VEXDRERIMPLZLU-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000001172 regenerating effect Effects 0.000 claims 2
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 claims 1
- ZMZQVAUJTDKQGE-UHFFFAOYSA-N 2-ethylhydracrylic acid Chemical compound CCC(CO)C(O)=O ZMZQVAUJTDKQGE-UHFFFAOYSA-N 0.000 claims 1
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 claims 1
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 1
- JVQYSWDUAOAHFM-UHFFFAOYSA-N 3-methyl-2-oxovaleric acid Chemical compound CCC(C)C(=O)C(O)=O JVQYSWDUAOAHFM-UHFFFAOYSA-N 0.000 claims 1
- QUKRTJQSGPLQKQ-UHFFFAOYSA-N 5-methylsulfonyl-3h-1,3-benzoxazol-2-one Chemical compound CS(=O)(=O)C1=CC=C2OC(=O)NC2=C1 QUKRTJQSGPLQKQ-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 claims 1
- 150000005693 branched-chain amino acids Chemical class 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 230000009756 muscle regeneration Effects 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818237P | 2013-05-01 | 2013-05-01 | |
| US61/818,237 | 2013-05-01 | ||
| PCT/US2014/036297 WO2014179526A1 (en) | 2013-05-01 | 2014-05-01 | Methods for enhancing aged muscle regeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520050A JP2016520050A (ja) | 2016-07-11 |
| JP2016520050A5 true JP2016520050A5 (enExample) | 2017-06-01 |
Family
ID=50885012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512033A Pending JP2016520050A (ja) | 2013-05-01 | 2014-05-01 | 老化筋肉再生の増強方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160066610A1 (enExample) |
| EP (1) | EP2999359A1 (enExample) |
| JP (1) | JP2016520050A (enExample) |
| CN (1) | CN105188413A (enExample) |
| BR (1) | BR112015027563A2 (enExample) |
| CA (1) | CA2911471A1 (enExample) |
| HK (1) | HK1221609A1 (enExample) |
| MX (1) | MX2015015178A (enExample) |
| PH (1) | PH12015502319A1 (enExample) |
| SG (1) | SG11201508388YA (enExample) |
| WO (1) | WO2014179526A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015094772A1 (en) * | 2013-12-18 | 2015-06-25 | Abbott Laboratories | Methods for increasing skeletal muscle protein synthesis using green tea extract |
| WO2016044272A1 (en) * | 2014-09-16 | 2016-03-24 | Abbott Laboratories | Methods of preserving muscle strength during a period of muscle disuse by administering beta-hydroxy-beta-methylbutyrate and green tea extract |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| US10596138B2 (en) | 2015-09-16 | 2020-03-24 | Abbott Laboratories | Reduced fat, shelf stable liquid nutritional composition |
| WO2017123922A1 (en) * | 2016-01-13 | 2017-07-20 | Metabolic Technologies, Inc. | COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR JOINT STABILITY |
| ES2811378T3 (es) * | 2016-04-01 | 2021-03-11 | Dsm Ip Assets Bv | Bebidas que comprenden gránulos estables de luteína molida |
| MX2018014407A (es) | 2016-05-25 | 2019-02-21 | Tsi Group Ltd | Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando. |
| US20210368843A1 (en) * | 2016-08-04 | 2021-12-02 | Seattle Gummy Company | Mineral compositions and methods of making and using thereof |
| CN109661180A (zh) * | 2016-08-04 | 2019-04-19 | 西雅图咖米公司 | 用于运动成绩的组合物及其制造和使用方法 |
| WO2018027081A1 (en) * | 2016-08-04 | 2018-02-08 | Seattle Gummy Company | Health management compositions and methods of making and using thereof |
| EP3528801B1 (en) | 2016-10-21 | 2024-07-17 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics |
| US12370159B2 (en) | 2016-10-21 | 2025-07-29 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics |
| BR112019023794A2 (pt) | 2017-06-09 | 2020-06-02 | Philip Morris Products S.A. | Artigo gerador de aerossol com segmento de filtro fibroso |
| US20190037904A1 (en) * | 2017-08-04 | 2019-02-07 | Sean R. Daly | Food-based protein formulation |
| MX392627B (es) * | 2018-02-09 | 2025-03-24 | Haldor Topsoe As | Proceso de produccion de compuestos de alfa-hidroxi y usos de los mismos |
| CN112312772A (zh) * | 2018-06-23 | 2021-02-02 | 西雅图咖米公司 | 用于降低咖啡因副作用的方法和组合物 |
| JP6541047B1 (ja) * | 2018-10-18 | 2019-07-10 | 株式会社東洋新薬 | 経口組成物 |
| CA3175049A1 (en) * | 2020-03-10 | 2021-04-15 | The Regents Of The University Of California | Novel nutrients to enhance load-induced muscle hypertrophy |
| WO2021236440A1 (en) | 2020-05-20 | 2021-11-25 | Advanced Food Concepts, Inc. | Athletic performance enhancement composition using menthol |
| CN112568444A (zh) * | 2020-11-20 | 2021-03-30 | 格乐瑞(无锡)营养科技有限公司 | 一种缓解肌肉流失的组合物及其制备方法 |
| WO2023190293A1 (ja) * | 2022-03-30 | 2023-10-05 | ニュートリー株式会社 | とろみ状栄養組成物 |
| WO2025030001A2 (en) * | 2023-08-02 | 2025-02-06 | Abbott Laboratories | Methods and compositions for maintaining skeletal muscle mobility and/or mass, and/or for recovery of skeletal muscle strength |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| ATE508745T1 (de) * | 2005-11-30 | 2011-05-15 | Novartis Pharma Gmbh | Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund |
| WO2007116962A1 (ja) * | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
| JP5507802B2 (ja) * | 2006-08-10 | 2014-05-28 | 花王株式会社 | 筋肉老化抑制剤 |
| EP3231435A1 (en) * | 2009-07-20 | 2017-10-18 | Nestec S.A. | Methods of attenuating the loss of functional status |
| CA2821312A1 (en) * | 2010-12-27 | 2012-07-05 | Abbott Laboratories | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate |
| WO2012097061A1 (en) * | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
| WO2012097064A1 (en) * | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for controlling blood glucose |
-
2014
- 2014-05-01 EP EP14728386.5A patent/EP2999359A1/en not_active Withdrawn
- 2014-05-01 HK HK16109844.1A patent/HK1221609A1/zh unknown
- 2014-05-01 CA CA2911471A patent/CA2911471A1/en not_active Abandoned
- 2014-05-01 US US14/888,314 patent/US20160066610A1/en not_active Abandoned
- 2014-05-01 MX MX2015015178A patent/MX2015015178A/es unknown
- 2014-05-01 SG SG11201508388YA patent/SG11201508388YA/en unknown
- 2014-05-01 WO PCT/US2014/036297 patent/WO2014179526A1/en not_active Ceased
- 2014-05-01 BR BR112015027563A patent/BR112015027563A2/pt not_active IP Right Cessation
- 2014-05-01 JP JP2016512033A patent/JP2016520050A/ja active Pending
- 2014-05-01 CN CN201480024698.9A patent/CN105188413A/zh active Pending
-
2015
- 2015-10-06 PH PH12015502319A patent/PH12015502319A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520050A5 (enExample) | ||
| Manns et al. | Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial | |
| RU2011129812A (ru) | Профилактика и лечение ротавирусной диареи | |
| WO2018084531A3 (ko) | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 | |
| JP2014528914A5 (enExample) | ||
| DE60336934D1 (de) | Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten | |
| Yamagata et al. | Epigallocatechin-3-gallate inhibits VCAM-1 expression and apoptosis induction associated with LC3 expressions in TNFα-stimulated human endothelial cells | |
| JP2011225596A5 (enExample) | ||
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| CN111479580A (zh) | 采用自噬诱发剂和高蛋白质的组合来诱发自噬的组合物和方法 | |
| JP2023025192A (ja) | 筋肉の質及び／又は筋量のためのオレウロペイン又はクルクミンを使用する組成物及び方法 | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2017105859A5 (enExample) | ||
| WO2006078424A3 (en) | Polyherbal compositions and methods for treating viral infections | |
| WO2007057748A2 (en) | Use of colostrum for the prophylaxis of influenza syndromes | |
| JP2019529569A5 (enExample) | ||
| JP2016534062A5 (enExample) | ||
| MX2010009640A (es) | Uso de conjugados de interleucina-1 en el tratamiento de diabetes. | |
| JP2014505679A5 (enExample) | ||
| RU2013133998A (ru) | Способы и композиции для предотвращения и лечения остеоартрита | |
| HRP20150363T1 (hr) | Kompozicije koje sadrže core-1 pozitivni mikroorganizam i njihova primjena za lijeäśenje ili profilaksu tumora | |
| WO2009019307A3 (en) | Oral calcitonin compositions and applications thereof | |
| JP5775096B2 (ja) | インフルエンザの治療剤または予防剤 | |
| JP2015500836A5 (enExample) | ||
| JP2012180331A (ja) | 筋損傷の早期回復の誘導用の経口摂取剤 |